Clinical trials · New York
Lung cancer clinical trials in New York
We’re tracking 277 recruiting lung cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 2/Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT06465069RecruitingPhase 1
Study of a new drug for advanced bladder and other solid tumors
This study tests a new drug (LY4052031) for people with several types of advanced solid tumors, especially bladder cancer. It aims to see if the drug is safe and effective when given alone or after other treatments have stopped working.
New York, New YorkAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
New York, New YorkAges 18 years+ - NCT06518057RecruitingPhase 2
Sparing memory during brain radiation for leptomeningeal metastases
This trial tests a special type of radiation that avoids the memory center of the brain (the hippocampus) while treating cancer that has spread to the lining of the brain and spinal cord. It may help reduce side effects on thinking and memory for people with breast or lung cancer.
New York, New YorkAges 18 years+ - NCT07619339RecruitingPhase 1
Tepotinib and Ivonescimab for MET-Driven Lung Cancer
This trial tests a combination of two drugs (tepotinib and ivonescimab) for advanced non-small cell lung cancer patients whose tumors have a specific genetic change called MET exon 14 skipping. The goal is to see if this combination can slow or shrink the cancer.
Uniondale, New YorkAges 18 years+ - NCT07080242RecruitingPhase 1
Study of a new drug for small cell lung cancer and neuroendocrine tumors
This trial tests a new drug called BL-M14D1 for people with certain types of advanced lung cancer or neuroendocrine tumors that have stopped responding to other treatments. It may be an option if your cancer has a specific marker called DLL3.
New York, New YorkAges 18 years+ - NCT05098132RecruitingPhase 1/Phase 2
STK-012 drug for advanced lung cancer and other tumors
This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.
Lake Success, New YorkAges 18 years+ - NCT06858813RecruitingPhase 1
ABBV-324 for advanced liver or lung cancer
This study tests an experimental IV drug (ABBV-324) for adults with advanced liver cancer (HCC) or advanced squamous lung cancer (LUSC). It aims to see if the drug is safe and whether it can help control the disease.
New York, New YorkAges 18 years+ - NCT07531095RecruitingPhase 1
Combination drug trial for small cell lung cancer
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
New York, New YorkAges 18–99 - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Mineola, New YorkAges 18 years+ - NCT07325136RecruitingPhase 1/Phase 2
BMS-986525 for Relapsed Small Cell Lung Cancer
This study tests a new drug called BMS-986525, alone or with other treatments, for people with small cell lung cancer that has come back or not responded to treatment. It aims to find out if the drug is safe and tolerable.
Buffalo, New YorkAges 18 years+ - NCT07174583RecruitingPhase 1/Phase 2
Study of IDE849 for DLL3-positive cancers like SCLC
This trial tests a new drug called IDE849 for cancers that make a protein called DLL3, including small cell lung cancer and some neuroendocrine tumors. It is for people whose cancer has progressed after standard treatments, and may be given alone or combined with other drugs like durvalumab or IDE161.
New York, New YorkAges 18 years+ - NCT07027514RecruitingPhase 1
Study of Tolododekin Alfa with immunotherapy for advanced lung cancer
This trial tests a new drug, Tolododekin Alfa, combined with an immunotherapy drug for advanced non-small cell lung cancer. It aims to see if this combination can help shrink tumors and improve outcomes.
New York, New YorkAges 18 years+ - NCT07249372RecruitingPhase 2
DRP-104 for a specific type of advanced lung cancer
This trial tests a new drug, DRP-104, for people with advanced non-small cell lung cancer that has a change in the NFE2L2 or KEAP1 genes. It is for people whose cancer has gotten worse after standard treatments like chemotherapy and immunotherapy.
New York, New YorkAges 18 years+ - NCT00301119Recruiting
Lung cancer screening using risk factors and test results
This study looks at how to find lung cancer earlier by screening people based on their lung-cancer risk. It may help doctors decide who needs further testing if lung nodules are found.
New York, New YorkAges 50 years+ - NCT07535463RecruitingPhase 1/Phase 2
Ivonescimab, chemotherapy, and radiation for lung cancer with brain tumors
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
Harrison, New YorkAges 18 years+ - NCT03851445RecruitingPhase 2/Phase 3
Lung cancer screening trial using tumor and blood test results
This trial helps sort people with previously treated lung cancer into the best next treatment options by using new tumor tissue (and sometimes blood) test results. It may help you get matched to therapies based on features like PD-L1 and other biomarkers.
The Bronx, New YorkAges 18 years+ - NCT04199741RecruitingPhase 1/Phase 2
PET/CT scan test for small cell lung cancer marker DLL3
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
New York, New YorkAges 18 years+ - NCT03808337RecruitingPhase 2
SBRT radiation plus standard treatment for spread cancer
This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.
Commack, New YorkAges 18 years+ - NCT07535437RecruitingPhase 1/Phase 2
New Drug Combination for Advanced Lung Cancer After Previous Treatment
This study tests a new combination of drugs (ivonescimab with either dato-DXd or osimertinib) for people with advanced lung cancer that has a specific EGFR gene mutation and has already been treated with other therapies. The goal is to see if this combination can help control the cancer better than current options.
Commack, New YorkAges 18 years+ - NCT05538130RecruitingPhase 1
Study medicine for BRAF-mutated advanced solid tumors
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
Brewster, New YorkAges 16 years+ - NCT07218601RecruitingPhase 2
Using breath testing to track lung cancer treatment
This trial uses a special breath test (E-Nose) to monitor how well treatment is working in people with non-small cell lung cancer. You just breathe into a device, and it measures compounds in your breath.
Commack, New YorkAges 18 years+ - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Lake Success, New YorkAges 18 years+ - NCT07462377RecruitingPhase 1
Testing EPI-326 for EGFR-mutant lung and head & neck cancers
This trial tests a new drug, EPI-326, in people with advanced lung or head & neck cancers that have certain EGFR changes. The goal is to see if it is safe and may help shrink the cancer.
Lake Success, New YorkAges 18 years+ - NCT03191149RecruitingPhase 2
Osimertinib for lung cancer with an EGFR exon 20 change
This Phase 2 study tests osimertinib (a targeted lung cancer pill) in people with advanced non-small cell lung cancer (NSCLC) whose tumors have an EGFR exon 20 insertion. It aims to see how well osimertinib works for this specific EGFR mutation and how safe it is.
Buffalo, New YorkAges 18 years+
Lung cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting lung cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 12 studies
- Memorial Sloan Kettering Nassau · 7 studies
- NYU Langone Health · 7 studies
- Memorial Sloan Kettering Commack · 6 studies
- Memorial Sloan Kettering Cancer Center - Westchester · 5 studies
- Columbia University Irving Medical Center · 4 studies
- Icahn School of Medicine at Mount Sinai · 3 studies
- Memorial Sloan Kettering Westchester · 2 studies
What taking part in a lung cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Lung cancer trials in other states
Common questions
- Are there lung cancer clinical trials in New York?
- Yes. We're currently tracking 277 recruiting lung cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.